Sinovac to Present at Inaugural China Healthcare Investment Conference
Press Release Source: Sinovac Biotech Ltd. On Tuesday March 23, 2010, 8:00 am EDT
BEIJING, March 23 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President and CEO of Sinovac, is scheduled to partake in Track One: Pharmaceuticals and Biotech at the Inaugural China Healthcare Investment Conference on March 30, 2010. Sinovac is one of five publicly traded life sciences companies that will make a 20-minute company presentation starting at 9:35 a.m. China Standard Time (CST). Mr. Yin will participate subsequently in the presenting company panel that commences at 10:35 a.m. CST. The conference will be held on March 29-31 at the Grand Hyatt in Shanghai, China.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
About China Healthcare Investment Conference
The China Healthcare Investment Conference is the premier event of its kind in China. As the leading event of the year focusing on rapidly-growing Chinese healthcare companies, the Conference will be a great opportunity to meet with emerging companies, industry leaders, key government officials and investors from China and the West.
Recognizing that the healthcare reform and industry growth is spurring a new wave of emerging Chinese healthcare companies, a group of sponsors including KPCB, Fidelity Asia Ventures, Vivo Ventures and Piper Jaffray are leading the efforts to organize this prestigious annual event. The group is committed to turn this meeting into a powerful platform to promote and nurture investment in healthcare in China, and further develop the industry.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
Media: Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
EN
